Cohen Joshua's most recent trade in Amylyx Pharmaceuticals Inc was a trade of 373,295 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharma Inc | Joshua B. Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 373,295 | 373,295 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Joshua B. Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 248,865 | 3,583,548 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Joshua B. Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.48 per share. | 02 Mar 2026 | 29,282 | 3,334,683 | - | 14.5 | 424,120 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.68 per share. | 02 Feb 2026 | 15,500 | 3,363,965 | - | 14.7 | 227,593 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.57 per share. | 15 Jan 2026 | 197,182 | 3,514,814 | - | 7.6 | 1,492,668 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 197,182 | 2,818 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Joshua Cohen B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.59 per share. | 15 Jan 2026 | 136,193 | 3,378,621 | - | 13.6 | 1,850,795 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 2,818 | 0 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Joshua Cohen B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.57 per share. | 15 Jan 2026 | 2,818 | 3,381,439 | - | 7.6 | 21,332 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 15 Jan 2026 | 1,974 | 3,379,465 | - | 13.8 | 27,299 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.09 per share. | 06 Jan 2026 | 7,715 | 3,317,632 | - | 11.1 | 85,596 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.34 per share. | 30 Sep 2025 | 29,733 | 3,325,547 | - | 14.3 | 426,469 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 30 Sep 2025 | 200 | 3,325,347 | - | 15 | 3,000 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 31 Mar 2025 | 21,490 | 3,355,280 | - | 3.5 | 74,482 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 270,177 | 270,177 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 180,118 | 3,376,770 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.17 per share. | 03 Mar 2025 | 4,595 | 3,196,652 | - | 3.2 | 14,549 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 03 Feb 2025 | 11,851 | 3,201,247 | - | 3.5 | 41,108 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.05 per share. | 06 Jan 2025 | 7,471 | 3,213,098 | - | 4.0 | 30,232 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 18,589 | 3,220,569 | - | 3.2 | 59,414 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 23 Sep 2024 | 1,857 | 3,239,158 | - | 1.6 | 2,915 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 1,857 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2024 | 34,449 | 1,857 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 12 Sep 2024 | 34,449 | 3,237,301 | - | 1.6 | 54,085 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 380,000 | 380,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 179,850 | 3,202,852 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 4,135 | 3,023,002 | - | 18.7 | 77,440 | Common Stock |
| Amylyx Pharma Inc | Cohen Joshua | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 126,667 | 3,027,137 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Cohen Joshua | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 5,841 | 2,900,470 | - | 16.3 | 95,372 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2023 | 63,694 | 36,306 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 16 Nov 2023 | 63,694 | 2,906,311 | - | 1.6 | 100,000 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 16 Mar 2023 | 96,076 | 2,796,541 | - | 31.8 | 3,059,021 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 50,000 | 2,842,617 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.45 per share. | 16 Mar 2023 | 3,924 | 2,792,617 | - | 32.4 | 127,315 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 4,122 | 2,894,463 | - | 36.1 | 148,717 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 1,846 | 2,892,617 | - | 36.8 | 67,912 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2022 | 334,520 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 05 May 2022 | 334,520 | 2,898,585 | - | 0.4 | 123,772 | Common Stock |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 337,500 | 337,500 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 75,000 | 2,564,065 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 2,489,065 | - | 0 | Common Stock | ||
| Amylyx Pharma Inc | Joshua Cohen | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 0 | - | - | Series C-1 Preferred Stock |